Skip to content

Endoscopic Management of Biliopancreatic Disease in the Lombardy Pancreas Units

Endoscopic Management of Suspected Biliopancreatic Disease Within the Lombardy Pancreas Units: a Prospective Observational Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07418164
Acronym
GENTLENESS
Enrollment
2500
Registered
2026-02-18
Start date
2026-10-31
Completion date
2027-07-01
Last updated
2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliopancreatic Diseases, Pancreatic Cancer, Periampullary Neoplasms

Brief summary

The GENTLENESS study is a prospective, multicenter, observational registry designed to evaluate the endoscopic management of patients with suspected biliopancreatic and periampullary neoplastic diseases within the Pancreas Units network of the Lombardy Region. Patients undergoing endoscopic ultrasound (EUS) for suspected pancreatic or periampullary malignancies, including pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumors, cystic pancreatic neoplasms requiring endoscopic, surgical, or oncological management, and periampullary tumors of the distal bile duct, ampulla, or duodenum, will be prospectively enrolled according to standard clinical practice. The study aims to assess the diagnostic accuracy of EUS-guided tissue acquisition, procedural safety, the need for repeat sampling, and organizational performance indicators, including time to definitive cyto-histological diagnosis and time to initiation of disease-specific treatment. No additional procedures beyond routine clinical care will be performed as a result of study participation.

Detailed description

Despite advances in oncological therapies, pancreatic cancer remains one of the leading causes of cancer-related mortality worldwide, with an increasing burden projected over the coming decades. The diagnostic and therapeutic pathway of biliopancreatic malignancies is complex and requires a high level of multidisciplinary expertise, particularly in high-volume referral centers organized as Pancreas Units. Endoscopic ultrasound (EUS) plays a central role in the diagnostic work-up of biliopancreatic and periampullary lesions, allowing high-resolution morphological assessment and, when indicated, tissue acquisition through fine-needle aspiration (FNA) or fine-needle biopsy (FNB). Accurate histological diagnosis is essential for therapeutic decision-making, including surgical planning, systemic therapy, and molecular profiling. The Lombardy Region has adopted a Hub-and-Spoke organizational model for Pancreas Units, defining minimum procedural volumes, expertise requirements, and performance benchmarks for referral centers. However, a centralized prospective system for monitoring endoscopic activity, diagnostic performance, and procedural outcomes across these centers is currently lacking. The GENTLENESS study has been designed to prospectively collect real-world data on EUS procedures performed in Lombardy Pancreas Unit Hub centers, with the primary objective of evaluating the diagnostic accuracy of EUS-guided biopsies. Secondary objectives include assessment of procedural volume, sampling techniques, need for repeat biopsies, complication rates, and time intervals from procedure to definitive diagnosis and initiation of treatment. The study is observational, does not introduce changes to clinical practice, and reflects routine patient management pathways. Any future analyses beyond the scope of the present registry will require separate Ethics Committee approval.

Interventions

None listed

Sponsors

IRCCS San Raffaele
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults (≥18 years) * Clinical, biochemical, and/or imaging suspicion of pancreatic neoplasia (adenocarcinoma, neuroendocrine tumors, cystic neoplasms requiring endoscopic, surgical, or oncological treatment) or periampullary neoplasia (distal bile duct, ampulla, duodenum) * Candidate for EUS according to standard clinical practice * Ability to understand and sign informed consent

Exclusion criteria

* Age \<18 years * Pregnancy or breastfeeding * Conditions other than those defined in the inclusion criteria * Inability to provide informed consent * Refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic Accuracy30 daysNumber of patients with a correct diagnosis obtained through EUS-guided cyto-histological sampling, confirmed by the final diagnosis

Secondary

MeasureTime frameDescription
Procedural Volume6 monthsNumber of EUS procedures performed for suspected biliopancreatic neoplasms
Need of Repeat Sampling30 days, 60 daysNeed for additional EUS-guided sampling after an initial non-diagnostic procedure
Sampling TechniqueIntraproceduralType of tissue acquisition (FNA vs FNB; ROSE vs MOSE)
Adverse EventsIntraprocedural, 30 daysIntra- and post-procedural complications classified according to ASGE criteria
Time to Diagnosis30 days, 60 daysTime from EUS to availability of definitive cyto-histological report
Time to Treatment30 days, 60 daysTime from diagnosis to initiation of disease-specific treatment

Countries

Italy

Contacts

CONTACTGaetano Lauri, PhDs
lauri.gaetano@hsr.it0226436303
CONTACTLaura Apadula, MSN
apadula.laura@hsr.it0226433979
PRINCIPAL_INVESTIGATORPaolo Giorgio Arcidiacono, Chief

IRCCS Ospedale San Raffaele

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 4, 2026